ATE550443T1 - Matrix-marker-modell und verfahren zur überprüfung und behandlung von rheumatischer arthritis - Google Patents

Matrix-marker-modell und verfahren zur überprüfung und behandlung von rheumatischer arthritis

Info

Publication number
ATE550443T1
ATE550443T1 AT08769291T AT08769291T ATE550443T1 AT E550443 T1 ATE550443 T1 AT E550443T1 AT 08769291 T AT08769291 T AT 08769291T AT 08769291 T AT08769291 T AT 08769291T AT E550443 T1 ATE550443 T1 AT E550443T1
Authority
AT
Austria
Prior art keywords
matrix
checking
rheumatic arthritis
treating rheumatic
marker model
Prior art date
Application number
AT08769291T
Other languages
German (de)
English (en)
Inventor
Chenglong Han
Wim Noel
Nathan Vastesaeger
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Application granted granted Critical
Publication of ATE550443T1 publication Critical patent/ATE550443T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Radar Systems Or Details Thereof (AREA)
AT08769291T 2007-05-03 2008-05-05 Matrix-marker-modell und verfahren zur überprüfung und behandlung von rheumatischer arthritis ATE550443T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91572407P 2007-05-03 2007-05-03
PCT/US2008/062621 WO2008137828A1 (en) 2007-05-03 2008-05-05 Matrix marker model and methods for assessing and treating arthritis and related disorders

Publications (1)

Publication Number Publication Date
ATE550443T1 true ATE550443T1 (de) 2012-04-15

Family

ID=39943976

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08769291T ATE550443T1 (de) 2007-05-03 2008-05-05 Matrix-marker-modell und verfahren zur überprüfung und behandlung von rheumatischer arthritis

Country Status (7)

Country Link
US (1) US20100145901A1 (enExample)
EP (1) EP2148934B1 (enExample)
JP (1) JP2010526303A (enExample)
AT (1) ATE550443T1 (enExample)
AU (1) AU2008247388A1 (enExample)
CA (1) CA2686260A1 (enExample)
WO (1) WO2008137828A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3042202A1 (en) 2013-09-03 2016-07-13 Graham, L. Douglas Treatment methods for rheumatoid arthritis
EP4502182A3 (en) * 2018-01-24 2025-07-09 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra)
JP7593797B2 (ja) * 2020-12-08 2024-12-03 キヤノンメディカルシステムズ株式会社 解析装置、解析システム及び解析方法
WO2023023338A1 (en) * 2021-08-19 2023-02-23 Navidea Biopharmaceuticals, Inc. Compositions and methods for the treatment of rheumatoid arthritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6187539A (ja) * 1984-09-19 1986-05-02 ヘルギ・ヴアルデイマーソン 慢性関節リウマチ患者の予後を補助するための方法及びこのような患者の病態活動の評価を補助するための方法
EP1212463A2 (en) * 1999-09-08 2002-06-12 The University Of British Columbia Diagnostic and therapeutic methods in autoimmune disease
WO2002022013A1 (en) * 2000-09-14 2002-03-21 The Board Of Trustees Of The Leland Stanford Junior University Assessing condition of a joint and cartilage loss
US20060141547A1 (en) * 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
US7702469B2 (en) * 2006-04-10 2010-04-20 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Systems and methods for predicting an individual's risk of developing rheumatoid arthritis

Also Published As

Publication number Publication date
HK1140797A1 (en) 2010-10-22
EP2148934A1 (en) 2010-02-03
CA2686260A1 (en) 2008-11-13
JP2010526303A (ja) 2010-07-29
EP2148934B1 (en) 2012-03-21
EP2148934A4 (en) 2010-07-07
US20100145901A1 (en) 2010-06-10
AU2008247388A1 (en) 2008-11-13
WO2008137828A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
MX2015016779A (es) Hidrogeles de poli(alquenilamida)-polisacarido para el tratamiento de formaciones subterraneas.
BR112017011956A2 (pt) composição de fraturamento hidráulico, método para fazer e uso da mesma
CY1125948T1 (el) Σχημα αγωγης που χρησιμοποιει νερατινιμπη για τον καρκινο του μαστου
NO20082658L (no) Fremgangsmåte for behandling av leddskade
EP2282737A4 (en) COMPOSITIONS AND METHODS FOR TREATING PERIODONTAL PATHOLOGY COMPRISING CLONIDINE, SULINDAC AND / OR FLUOCINOLONE
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
BRPI0911482A2 (pt) Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer
MX2012011722A (es) Diseño automatico de tratamientos de fracturamiento hidraulico que utiliza la altura de la fractura y la presion in situ.
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
MX378834B (es) El uso de un inhibidor de c1-esterasa para el tratamiento del rechazo mediado por anticuerpos en pacientes con trasplante de órganos.
BR112012026224A2 (pt) métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
EA201071422A1 (ru) Способы лечения заболеваний, связанных с мейотическим кинезином
ATE550443T1 (de) Matrix-marker-modell und verfahren zur überprüfung und behandlung von rheumatischer arthritis
TR201905392T4 (tr) Ağrı tedavisi.
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
WO2012074550A3 (en) Methods to assess treatment outcomes in reward deficiency syndrome (rds) behaviors utilizing expression profiling
BR112018076935A2 (pt) composição, medicamento e método para o tratamento da alopecia induzida por quimioterapia
PH12014502282A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
CO2017011472A2 (es) Métodos de tratamiento de plantas de cultivo
BR112016016842A2 (pt) Composição compreendendo um herbicida seletivo e um extrato de algas, uso de um extrato de algas para desintoxicar plantas submetidas ao tratamento com um herbicida seletivo